Melissa Young, MD
Endocrinology, Diabetes & Metabolism · Freehold, NJNPI 1831174739
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.9%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 57.2% of the total. 2025 is the largest year on record at $11,535, 4.1 times the $2,787 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 645 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$12K
- Novo Nordisk$2K
- Lilly USA, LLC$881
- AstraZeneca$709
- Insulet Corporation$700
- Mannkind Corporation$466
- plus $4K from 45 others
What the payments were for
- Consulting fees$10,17050%
- Speaking & faculty fees$6003%
- Travel & lodging$3822%
- Food & beverage$9,18645%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,390 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 345 | $719,638 |
| JardianceEmpagliflozin | 223 | $293,393 |
| MounjaroTirzepatide | 74 | $152,197 |
| FarxigaDapagliflozin Propanediol | 106 | $146,433 |
| TrulicityDulaglutide | 85 | $136,262 |
| InvokanaCanagliflozin | 55 | $76,838 |
| RybelsusSemaglutide | 47 | $75,000 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $67,935 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 34 | $63,210 |
| JanuviaSitagliptin Phosphate | 40 | $55,423 |
| SynthroidLevothyroxine Sodium | 479 | $48,313 |
| Tresiba Flextouch U-100Insulin Degludec | 58 | $46,927 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 24 | $43,316 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $34,109 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $31,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,885 | $814,979436 claims |
| Boehringer IngelheimJardiance, Tradjenta | $461 | $321,873266 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $881 | $307,745215 claims |
| AstraZenecaFarxiga | $709 | $146,433106 claims |
| MerckJanuvia, Janumet Xr, Janumet | $252 | $108,56783 claims |
| Johnson & JohnsonInvokana | $91 | $76,83855 claims |
| AbbVieSynthroid | $128 | $48,313479 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $162 | $7,348636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Freehold
- Kenneth OrdeneFreehold$109K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.